Ignite Creation Date:
2024-05-05 @ 5:24 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00446329
Status:
TERMINATED
Last Update Posted:
2014-10-29
First Post:
2007-03-09
Brief Title:
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
Sponsor:
Papageorgiou General Hospital
Organization:
Papageorgiou General Hospital
Study Overview
Official Title:
None
Status:
TERMINATED
Status Verified Date:
2014-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
due to financial problems
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The 1st phase of the study will assess the acute biochemical response of PTH calcium and phosphorus to orally administered doses of cinacalcet once 60mg or twice 30mg x 2 per day
The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD bone mineral densityand the levels of PTH calcium phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds
The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD bone mineral densityand the levels of PTH calcium phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None